Correlation of T cell fitness of apheresis products with response to CAR T-cell therapy in patients with relapsed or refractory large B-cell lymphoma: A prospective observational study at a single center
Observational study links memory T cells and immune profiling to response in CAR T-cell therapy for large B-cell lymphoma, suggesting viability of pretreatment biomarkers.
Key Points
To evaluate the correlation of T cell fitness in apheresis products with patient responses to CAR T-cell therapy.
Conducted a prospective observational study in patients with relapsed/refractory large B-cell lymphoma
Performed immune profiling of apheresed T cells using multicolor flow cytometry
Examined T cell characteristics using markers such as CD45RA, CCR7, and PD-1
Analyzed effects of chemotherapy on T cell subsets in lymphoma patients
Durable remission associated with higher frequencies of memory T cells in apheresed products
Significant differences in T cell clusters observed between remission and refractory/relapsed cases
Chemotherapy negatively impacted memory T cell frequencies, particularly with bendamustine regimens